Detailed Information on Publication Record
2018
Genomagnetic LAMP-based electrochemical test for determination of high-risk HPV16 and HPV18 in clinical samples
BARTOŠÍK, Martin, Ludmila JIRÁKOVÁ, Milan ANTON, Bořivoj VOJTĚŠEK, Roman HRSTKA et. al.Basic information
Original name
Genomagnetic LAMP-based electrochemical test for determination of high-risk HPV16 and HPV18 in clinical samples
Authors
BARTOŠÍK, Martin (703 Slovakia, guarantor), Ludmila JIRÁKOVÁ (203 Czech Republic), Milan ANTON (203 Czech Republic, belonging to the institution), Bořivoj VOJTĚŠEK (203 Czech Republic) and Roman HRSTKA (203 Czech Republic)
Edition
Analytica Chimica Acta, Amsterdam, Elsevier Science publishers, 2018, 0003-2670
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30214 Obstetrics and gynaecology
Country of publisher
Netherlands
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 5.256
RIV identification code
RIV/00216224:14110/18:00105867
Organization unit
Faculty of Medicine
UT WoS
000448290800005
Keywords in English
HPV; Cervical cancer; Genomagnetic assay; Electrode chip; LAMP amplification
Tags
International impact, Reviewed
Změněno: 23/4/2024 10:09, Mgr. Michal Petr
Abstract
V originále
Major cause of cervical cancer is a persistent infection with high-risk types of human papillomaviruses (HPV). For that reason, HPV testing is now becoming an important addition to standard cytological screening of cervical malignancies in women (known as Pap test). New methods are sought which could offer rapid and inexpensive detection schemes, such as those based on electrochemical (EC) readout. Here, we developed an assay for parallel detection of two most oncogenic high-risk HPV types, HPV16 and HPV18, by combining loop-mediated amplification (LAMP) of template DNA, its separation using magnetic beads and detection with amperometry at carbon-based electrode chips. Our EC-LAMP test enabled us to successfully discriminate both HPV types not only in cancer cell lines, but also using clinical material obtained from HPV-positive patient samples. (C 2018 Elsevier B.V. All rights reserved.